Vertex Pharmaceuticals has partnered with TreeFrog Therapeutics to obtain an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-Stem. This collaboration aims to optimize the production of Vertex’s cell therapies for type 1 diabetes (T1D). TreeFrog’s technology is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D. By scaling up TreeFrog’s process, Vertex will be able to generate large amounts of fully differentiated cells for its T1D therapies.